- 1 Title: Neurodevelopmental outcomes of infants secondary to in utero exposure to maternal
- 2 SARS-CoV-2 infection: A national prospective study in Kuwait
- <sup>1</sup>Mariam Ayed, <sup>1</sup>Alia Embaireeg, <sup>2</sup>Mais Kartam, <sup>3</sup>Kiran More, <sup>4</sup>Mafaza Alqallaf, <sup>5</sup>Abdullah
- 4 AlNafisi, <sup>2</sup>Zainab Alsaffar, <sup>4</sup>Zainab Bahzad, <sup>2</sup>Yasmeen Buhamad, <sup>6</sup>Haneen Alsayegh, <sup>7</sup>Wadha
- 5 Al-Fouzan, <sup>2</sup>Hessa Alkandari
- <sup>1</sup>Mariam Ayed, MD, FAAP, FRCPC Neonatal Department, Farwaniya Hospital, Kuwait. Email:
- 7 mariam.ayed@hsc.edu.kw
- <sup>1</sup>Alia Embaireeg, MD, KBP. Neonatal Department, Farwaniya Hospital, Kuwait. Email:
- 9 a.embaireeg@gmail.com
- <sup>2</sup>Mais Kartam, MD. Paediatric Department, Farwaniya Hospital, Kuwait. Email:
- 11 maiskartam94@hotmail.com
- <sup>3</sup>Kiran Moore. MD. Division of Neonatology, Sidra Medicine, Doha, Qatar. Weill Cornell
- 13 Medicine, Doha, Qatar
- <sup>4</sup>Mafaza Alqallaf, MD. Paediatric Department, Adan Hospital, Kuwait. Email:
- 15 mafaza.alqallaf@gmail.com
- <sup>5</sup>Abdullah AlNafisi, MD. Paediatric Department, Sabah Hospital, Kuwait. Email:
- 17 a.nafisi@outlook.com
- <sup>2</sup> Zainab Alsaffar, MD. Paediatric Department, Farwaniya Hospital, Kuwait. Email:
- 19 zainabys@hotmail.com
- <sup>4</sup>Zainab Bahzad, MD. Paediatric Department, Adan Hospital, Kuwait. Email:
- 21 Zainab20bahzad@gmail.com

22	<sup>5</sup> Yasmeen Buhamad, MD. Paediatric Department, Farwaniya Hospital, Kuwait. Email: YHB-
23	95@live.com
24	<sup>6</sup> Haneen Alsayegh, MD. Paediatric Department, Amiri Hospital, Kuwait. Email:
25	H_alsayegh5@hotmail.com
26	<sup>7</sup> Wadha Al-Fouzan, MD. Department of Microbiology, Faculty of Medicine, Kuwait University,
27	Jabriya, Kuwait. Email: alfouzan.w@ku.edu.kw
28	<sup>2</sup> Hessa Alkandari, MD. Pediatric Department, Farwaniya Hospital, Kuwait. Email:
29	hessa.alkandari@dasmaninstitute.org
30	CORRESPONDING AUTHOR:
31	Mariam Ayed, Neonatal Department, Farwaniya Hospital, Subah An Nasser, Kuwait City, Postal
32	code-81400, Kuwait, Tel: 965-98880553, Mariam.ayed@hsc.edu.kw
33	
34	
35	
36	
37	
38	
39	
40	

41 **Abstract** 42 Background 43 An increasing proportion of women are being infected with severe acute respiratory syndrome 44 coronavirus 2 (SARS-CoV-2) during pregnancy. Intrauterine viral infections induce an increase 45 in the levels of proinflammatory cytokines, which inhibit the proliferation of neuronal precursor 46 cells and stimulate oligodendrocyte cell death, leading to abnormal neurodevelopment. Whether a maternal cytokine storm can affect neonatal brain development is unclear. The objective of the 47 48 present study is to assess neurodevelopmental outcomes in neonates born to mothers with SARS-49 CoV-2 infections during pregnancy. Methods 50 51 In this prospective cohort study, the neurodevelopment status of infants (N=298) born to women 52 with SARS-CoV-2 infections during pregnancy was assessed at 10-12 months post discharge using the Ages and Stages Questionnaire, 3rd edition (ASQ-3). The ASQ-3 scores were 53 54 classified into developmental delays (cutoff score: ≤2 standard deviations (SDs) below the 55 population mean) and no delay (score >2 SDs above the population mean). 56 Results 57 Approximately 10% of infants born to mothers with SARS-CoV-2 infections during pregnancy 58 showed developmental delays. Two of 298 infants tested positive for SARS-CoV-2, and both had normal ASQ-3 scores. The majority of the pregnant women had SARS-CoV-2 infection 59 60 during their third trimester. The risk of developmental delays among infants was higher in those 61 whose mothers had SARS-CoV-2 infections during the first (P=0.039) and second trimesters 62 (P=0.001) than in those whose mothers had SARS-CoV-2 infections during the third trimester.

Infants born at <31 weeks gestation were more prone to developmental delays than those born at

>31 weeks gestation (10% versus 0.8%; P=0.002).

Conclusion

The findings of the study highlight the need for long term neurodevelopmental assessment of

infants born to mothers with SARS-CoV-2 infection.

**Key Words**: Coronavirus 2019 (SARS-CoV-2), Pregnancy, Neurodevelopment of infants,

Perinatal transmission

variable effects on the fetus [1,2].

## **Background**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease-19 (COVID-19), has been spreading rapidly worldwide, increasingly affecting even pregnant females. Pregnancy-associated physiological changes, as well as altered cell-mediated immunity, enhance the susceptibility of pregnant women to infections by intracellular organisms such as viruses. Based on a living systematic review and meta-analysis, overall, 10% (95% confidence interval (CI): 7-12%; 73 studies involving 67271 women) of pregnant and recently pregnant women attending or admitted to the hospital for any reason were diagnosed as having suspected or confirmed SARS-CoV-2 infection [1]. Hence, a growing proportion of pregnant women become infected with SARS-CoV-2 during various trimesters of pregnancy, with

Furthermore, the underdeveloped innate and adaptive immune systems of fetuses and neonates

also make them more susceptible to infections [3, 4]. Maternal-fetal transmission of SARS-CoV-

2 has not been widely established to date, and findings vary. A meta-analysis revealed that

vertical transmission of SARS-CoV-2 is possible and-showed that only 3.2% (27 of 936; 95% CI: 2.2-4.3) of neonates from mothers infected with SARS-CoV-2 had a positive result based on viral RNA testing of nasopharyngeal swabs [5]. SARS-CoV-2 viral RNA testing was positive in neonatal cord blood (2.9% samples), placental swabs (7.7%), and fecal or rectal swabs, whereas it was negative in urine and amniotic fluid samples. In contrast, a more recent systematic review article (2021), which covered the database up to September 2020, reported that newborn rates of the infection vary between 0% and 11.5% [6]. Nevertheless, due to the availability of only a few patients and studies, the exact rates of vertical transmission and fetal or neonatal morbidity and mortality cannot be ascertained.

Although SARS-CoV-2 primarily causes respiratory distress, it is also known to have extrapulmonary manifestations, including hematological, cardiovascular, endocrinological, and neurological complications, in the adult population [7-9]. Of these, neurological manifestations in pregnant women and their probable effect on fetuses and neonates are of primary concern. SARS-CoV-2 may gain entry into the central nervous system through the nasal mucosa, lamina cribrosa, and olfactory bulb or through retrograde axonal transport. SARS-CoV-2 also exhibits neurovirulence, triggering proinflammatory and prothrombotic cascades in the wake of cytokine storms, affecting brain vasculature, as well as the blood-brain barrier, mainly in the setting of the toxic-metabolic sequelae of multiorgan dysfunction frequently observed in SARS-CoV-2-positive patients [10,11]. Proinflammatory cytokines inhibit the proliferation of neuronal precursor cells, activate astrogliosis, and stimulate oligodendrocyte cell death, leading to abnormal neurodevelopment [3, 4]. Moreover, the elevated levels of maternal inflammatory cytokines (IL-1, IL-6, IL-8, and TNF-α) as a consequence of infection during pregnancy can

disturb several characteristics of fetal brain development [12]. Notably, these pathological changes, which include deteriorated neuronal functions and atypical behavioral changes, can subsequently be seen in postnatal life and may increase the risk of schizophrenia, autism, and mental disorders [12, 13].

Additionally, animal studies have shown that offspring from maternal immune activation animal models have schizophrenia and autism-related behaviors, including decreased sensorimotor gating, deficits in working memory and cognitive flexibility, increased anxiety, and enhanced sensitivity to amphetamines [14-16].

Because of the plausible effects on neonates born to mothers with SARS-CoV-2 infections during pregnancy, this study assessed the developmental attainment at 10-12 months of neonates born to a cohort of mothers with SARS-CoV-2 infections during pregnancy in Kuwait using the Ages and Stages Questionnaire, 3rd edition (ASQ-3).

### 2 Methods

### 2.1Participants

In this prospective cohort study, infants born between April 1 and August 30, 2020, to mothers with SARS-CoV-2 infection during various trimesters of pregnancy were evaluated. Pregnant women who tested positive by reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 (Cobas 6800 Systems, Roche, Switzerland)/(TaqPath, Thermo-Fisher Scientific, USA) were identified from the Kuwait National COVID-19 registry. Mothers with equivocal RT-PCR test results and those with missing data were not included in the study. Verbal informed

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

consent was obtained from all the parents who participated in the study. Ethics approval was granted by the Ministry of Health, (2021-1638), Government of Kuwait. Demographic details were collected for all infants enrolled in the follow-up study. Maternal clinical and neonatal data from acute hospital admissions were collected by retrospective chart review of the included participants and have been previously published [17]. 2.2 Instrument The ASQ-3 (http://agesandstages.com/) is a widely used screening tool for assessing development in children aged 1-66 months at a low cost, with cutoff scores identifying developmental delays. The screening tool has strong validity, and its use has been widespread in assessing development in children [18]. The ASQ-3 has five domains: communication, gross motor skills, fine motor skills, problem-solving capacity, and personal-social development. In the current study, we used the ASQ-3 to assess neurodevelopmental outcomes at 10-12 months postdischarge. Parents of infants completed the ASQ-3, which has a series of 21 developmental screening questions. Three study investigators (MAL, MK, and AE) scored the questionnaire results using the ASQ-3 age-specific scoring sheet. In each domain, six items were scored as present in the infant, sometimes present or not yet shown by the infant, with 10, 5, and 0 points, respectively. If an item was not filled in, a score of 0 was assigned based on the lowest possible result. Responses were summed to give a score of 0 to 60 for each domain and an overall maximum ASQ-3 score of 300 points. ASQ-3 results were categorized according to questionnaire-defined subscale cutoff scores into 1) developmental delays, with an ASQ-3 cutoff score of  $\leq 2$  standard deviations (SDs) below the population mean on 1 or more domains, and 2) no delay, with a cutoff score >2 SDs above the population mean [18].

The questionnaire was sent in two languages: the Arabic version for Arabic-speaking parents and the English version for non-Arabic-speaking parents. The questionnaire was completed by parents and reviewed in a telephone interview with one investigator. Parents were encouraged to provide their responses with their interpretation without prompting.

## 2.3 Statistical analysis

All data were entered into a Microsoft Excel database. Categorical variables were summarized as counts (n) and percentages (%), and continuous variables were summarized as the median and interquartile range (IQR). Statistical comparisons between the groups were performed using the chi-squared test for categorical variables and the Wilcoxon rank-sum test for continuous variables.

We performed a multivariate logistic regression analysis for each potential predictor of developmental delays. Variables with a P value of <0.1 on the univariate analysis were included in the model (maternal age and trimester at SARS-CoV-2 infection) and adjusted for gestational age, birth weight, sex, parental education and type of feeding in the first 6 months of age. The results of the regression analysis are presented as an adjusted odds ratio (aOR) with a 95% CI. Statistical significance was taken at P<0.05. Statistical analysis was performed with **STATA 14** software (**Stata** Corporation, College Station, TX).

#### 3 Results

Eight hundred forty pregnant women were identified from the national COVID-19 registry between April 1 and August 30, 2020. Four hundred forty-five women gave birth during the

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

study period (Figure 1). One infant died on the first day of life due to severe birth asphyxia; 298 (67%) had complete follow-up at 10-12 months corrected age, and 146 (32.8%) infants were lost to follow-up. The main reason for the loss to follow-up was the inability to contact the parents due to either invalid contact information or parents having left the country. To determine whether the infants we lost to follow-up were representative of the complete study and to avoid attrition bias, we compared the baseline features of those infants with follow-up data with the baseline features of infants who were lost to follow-up. We did not find any statistically significant differences between these two groups. The maternal and neonatal characteristics of the cohort are shown in **Table 1**. Among the infants with completed ASQ-3, 5 (1.7%) were born to mothers diagnosed with SARS-CoV-2 during the first trimester, 20 (6.7%) during the second trimester, and 273 (91.6%) during the third trimester. Only 2 (0.7%) neonates tested positive for SARS-CoV-2 infection. Twenty-eight infants needed hospitalization beyond the first 8-10 months of age. Parental questionnaires were collected at a median of 10.3 months corrected age (IQR 10 to 12.7). Developmental delays were identified in 30 (10.1%) of the infants. Of those with developmental delays, 3.3% (1/30) had delays in the communication domains, 27% (8/30) in the gross motor domain, 40% (12/30) in the fine motor domain, 10% (3/30) in the problem-solving domain, and 30% (9/30) in the personal-social domain (Figure 2). In the infants with developmental delays, 4 had concerns in two or more domains, and none had concerns in all domains. Infants with developmental delays did not differ in terms of maternal age, maternal comorbidities, parental education level, severe maternal COVID-19, or the mode of delivery

compared to those with no delay (**Table 2**). However, the occurrence of developmental delays differed significantly on the basis of the trimester at SARS-CoV-2 infection. Developmental delays were more common in infants born to mothers with COVID-19 during the first and second trimesters than in infants born to mothers with COVID-19 during the third trimester (P<0.001). Among infants with developmental delays, 4 (13.3%) were born to mothers with SARS-CoV-2 infection during the first trimester, 6 (20%) were born to mothers with SARS-CoV-2 infection during the second trimester, and 20 (66.7%) were born to mothers with SARS-CoV-2 infection in the third trimester. One (0.4%) of the infants without delay was born to a mother with SARS-CoV-2 infection in the first trimester, 14 (5.2%) were born to mothers with SARS-CoV-2 infections in the second trimester, and 253 (94.4%) were born to mothers with SARS-CoV-2 infections in the third trimester. Moreover, infants born at less than 31 weeks gestation were more likely to have developmental delays than infants born at more than 31 weeks gestation (10% versus 0.8%; P=0.002). Neonatal characteristics were similar between the groups. In multivariate logistic regression analysis, adjusting for maternal age, parental educational level, gestational age, birth weight, and the type of feeding in the first six months of age, the risk of developmental delays was higher with first-trimester maternal SARS-CoV-2 infection (aOR: 8.2, 95% CI: 1.1-55.9; P=0.039) and second-trimester maternal SARS-CoV-2 infection (aOR: 8.1, 95% CI: 2.4-27.7; P=0.001) than with third-trimester maternal SARS-CoV-2 infection (**Table 3**).

### **4 Discussions**

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

The fetal inflammatory response (FIRS) due to maternal SARS-CoV-2 infection can contribute to severe neonatal morbidity, which includes stillbirth, neonatal death, preterm birth, low birth

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

weight, fetal distress, and neonatal asphyxia [19-21]. This is perhaps the first study reporting neurological assessments of neonates born to mothers from West Asia with SARS-CoV-2positive RT-PCR test results during pregnancy using the ASQ-3. The findings of this study indicate that infants born to mothers who test positive for SARS-CoV-2 infection during pregnancy need to be assessed for neurodevelopmental delays. To assess the developmental attainment of infants born to mothers with SARS-CoV-2-positive test results during pregnancy, this study employed the ASQ-3, a screening tool used for assessing the developmental attainment of infants and young children [18]. This screening tool is used widely in assessing development in children aged 1–66 months at a low cost, with cutoff scores identifying developmental delays. In the current study, an Arabic version of the ASQ-3 was used for mothers who were well versed in Arabic. Since the study cohort included diverse as well as immigrant mothers, questionnaires were sent to mothers, and fortunately, the majority of them consented to respond. The study data revealed that the majority (91.6%) of the pregnant women had SARS-CoV-2 infection during their third trimester, whereas 6.7% had SARS-CoV-2 infection in their second trimester. This finding is in agreement with those of other studies that have also reported that most SARS-CoV-2 infections in pregnant women occur in their third trimester [22, 23]. In the current study, only a relatively small number of women were infected during the first trimester. However, first-trimester infections are important as the principal stages of brain development, such as primary neurulation (weeks 3-4), prosencephalic development (months 2-3), and neuronal proliferation (months 3-4), occur during the early stages of pregnancy [24]. In fact,

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

infections with some common pathogens, such as cytomegalovirus (CMV), Zika virus, Rubella virus, Mycobacterium tuberculosis (TB), and Toxoplasma gondii, during the first and early second trimesters increase the risk of symptomatic infants, with up to 32% being associated with neurological manifestations [25]. Owing to the relatively recent emergence of COVID-19, information related to pregnancy outcomes among women with SARS-CoV-2 infection and the consequences of infant exposure to the virus is very scarce. As more women become infected during their first and second trimesters progress in their pregnancy and as newborns with SARS-CoV-2 infection develop, a better understanding of the neurological effects of this novel virus will emerge. In brief, various types of evidence support the theory that maternal infection and/or inflammation occurring during critical periods of fetal development could alter brain structure and function in a time-sensitive manner. Nevertheless, SARS-CoV-2 infection increases the chances of fetal distress, leading to high incidences of admission to the neonatal intensive care unit (NICU) [23]. Similar to other reported studies, in the current study, 76 out of 298 (25.5%) neonates born to mothers with SARS-CoV-2infection during pregnancy required NICU admission [26-29]. On the other hand, a systematic review reported that approximately 95% of neonates born to mothers with SARS-CoV-2 infection during pregnancy were born in good condition [1]. Recent evidence suggests that vertical transmission of SARS-CoV-2 either antenatally or intrapartum can occur, but it is uncommon. In this study, only 2 (0.7%) neonates tested positive for SARS-CoV-2 infection, and notwithstanding some seemingly perinatal complications, the majority of neonates (296 out 298) born were negative for SARS-CoV-2 infection. Our observation is in agreement with those of other studies [30-32], which implies that the

consequences of SARS-CoV-2 infection on neurodevelopment were largely due to in utero effects rather than direct effects on the fetus. The reason for the low vertical transmission rate is that the placenta has low expression of the canonical receptors necessary for viral entry, which may explain the rarity of vertical transmission of SARS-CoV-2 [32]. Importantly, teratogenic effects of SARS-CoV-2 on the fetus were not observed, which is in contrast to other viral infections, such as Middle East respiratory syndrome coronavirus, CMV, herpes virus, Zika virus, and Rubella virus infections [33-37].

In this study, we evaluated the infant's neurobehavioral development 10-12 months post discharge, perhaps the adequate duration for effects to appear. In this study, overall, 69.1% of neonates at the end of 10-12 months showed normal developmental attainment, and only 10.1% (n=30) showed developmental delays. The PregCOV-19 living systematic review [1] found that approximately 95% of neonates born to SARS-CoV-2-positive mothers were reported to be born in good condition. However, it is not clear whether this systematic review included evaluations of neurodevelopmental delays in neonates. A study from the UK, in which information about educational and behavioral problems was collected from 177 children, found that 25% required support from a nonteaching assistant, 4% required a statement of special educational needs, and 3% were in a special school [38]. Many investigators have studied the effects of various viral infections, albeit not SARS-CoV-2, on pregnancy and fetal/neonatal outcomes and have reported that maternal influenza, hepatitis C, varicella-zoster, and other viruses produce distinct fetal brain structure and anatomy clinical pathology of varying severity [39-42].

Of note, the role of cytokine storms, particularly the role of IL-6 in the pathogenesis of neurodevelopmental disorders, is not fully elucidated; however, in a longitudinal study, alterations in brain architecture, executive function, and working memory abilities were reported in 2-year-old neonates exposed to increased IL-6 levels during pregnancy [43]. An analysis of 214 patients with SARS-CoV-2 infection revealed that 36% had neurological symptoms [44]. Many case-control studies have demonstrated that elevated maternal cytokine levels affect the fetal brain, causing neurological disease [45-47]. The FIRS, due to increased IL-6 following maternal SARS-CoV-2 infection [13], may induce a wide range of adverse neurodevelopmental sequelae, such as autism, psychosis, and neurosensory deficits, later in life [48], similar to certain bacterial infections [49]. However, long-term longitudinal studies are required to validate these associations.

Moreover, the risk of neurological effects on neonates differs by the trimester when SARS-CoV-2 infection occurred [50]. In this study, developmental delays were relatively more prevalent when infection occurred in the first and second trimesters than when infection occurred in the third trimester (P<0.001). Neonatal characteristics were similar between the groups. Moreover, infants born at less than 31 weeks gestation were more likely to have developmental delays than those born at more than 31 weeks gestation (10% versus 0.8%; P=0.002).

The findings of the study may be considered reliable, as the cohort of parents who participated in the study was well educated, and women were young (median age: 31 years). Three-fourths of women were devoid of pregnancy-induced hypertension or gestational diabetes.

#### **5 Strength and Limitations**

This is perhaps the first study reporting neurological assessments of neonates born to mothers with SARS-CoV-2-positive RT-PCR test results during pregnancy using the ASQ-3. The participating mothers were from the local area, which enabled good tracking for follow-ups. Participants were educated and responded to ASQ-3 questions appropriately. Thus, these points may be regarded as strength of the study.

This study also has a few limitations, the most important aspects of which are related to the sample size and methodology. For stronger conclusions, a larger and statistically valid sample size is required. Furthermore, the ASQ-3 were completed by the parents of the neonates; hence, biases in reporting cannot be ruled out. Nevertheless, this initial study may help healthcare authorities understand the need to assess the developmental attainment of infants born to mothers with SARS-CoV-2-positive test results during pregnancy. The ASQ-3, although a good screening tool, has limitations, and its results may not be strongly comparable to those of other tools, such as the Bayley III test; therefore, further larger studies with formal assessments of neurodevelopment are warranted.

### **6 Conclusions**

This study was a hypothesis-generating study, and the findings based on a screening tool raise some concerns regarding neurodevelopmental effects on fetuses born to mothers with SARS-CoV-2-positive test results during pregnancy. A majority of the pregnant women had SARS-CoV-2 infections during their third trimester. Developmental delays were more prevalent when SARS-CoV-2 infection occurred in the first and second trimesters than when it occurred in the third trimester. Infants born at less than 31 weeks gestation were more likely to have

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

developmental delays than those born at more than 31 weeks gestation. Further larger studies with formal developmental assessments are warranted to study the effect of SARS-CoV-2 on the developing brain. **Abbreviations** MIS-N: Multisystem inflammatory syndrome in neonates SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2 COVID-19: Coronavirus disease 2019 RT-PCR: Reverse transcriptase-polymerase chain reaction CDC: Centers for Disease Control CRP: C-reactive protein IL: Interleukin FIRS: Fetal inflammatory response **Declarations:** Ethics approval and consent to participate Ethics approval was granted by the Ministry of Health, (2021-1638), Government of Kuwait. Availability of data and materials

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

Not applicable **Competing interests** The authors declare that they have no competing interests **Funding** None **Authors' contributions** MA conceptualized and planned the study design, planned data collection, oversaw data collection, literature review, performed the text mining analysis, drafted and revised the final version of the manuscript. MA also performed the statistical analysis. AE, MK, MA, ZA, ZB, YB and HA conducted the literature review, contributed to the writing and reviewing of the manuscript. All other co-authors contributed to data collection and oversaw the manuscript. Acknowledgements We would like to thank the respective register holders; Maternal and Perinatal COVID-19 Kuwait National Registry. **References:** 1. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020; doi: https://doi.org/10.1136/bmj.m3320.

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

2. la Cour Freiesleben N, Egerup P, Hviid KVR, Severinsen ER, Kolte AM, Westergaard D.SARS-CoV-2 in first trimester pregnancy: a cohort study. Hum Reprod. 2021;doi: 10.1093/humrep/deaa311. 3. Marodi L. Neonatal innate immunity to infectious agents. Infect Immun. 1999–2006 doi:10.1128/IAI.74.4.1999-2006.2006. 4. van Well GTJ, Daalderop LA, Wolfs T, Kramer BW. Human perinatal immunity in physiological conditions and during infection. Mol Cell Pediatr.2017; doi:10.1186/s40348-017-0070-1. 5. Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021;doi.org/10.1016/j.ajog.2020.07.049. 6. Vergara-Merino L, Meza N, Couve-Perez C, Carrasco C, Ortiz-Munoz L, Madrid E, Bohorquez-Blanco S, Preze-Bracchiglinoe J. Maternal and perinatal outcomes related to COVID-19 and pregnancy: An overview of systematic of systematic reviews. Acta Obstet Gynecol Scand. 2021; doi: 10.1111/aogs.14118. 7. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;doi: 10.1056/NEJMoa2002032.

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; doi: 10.1016/S0140-6736(20)30566-3. 9. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020:**75**:2352–71. 10. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2020; doi:10.1182/blood-2018-11-882993. 11. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet.2020;doi:10.1016/S0140-6736(20)30628-0. 12. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol.2017; doi.org/10.1038/nri.2017.64. 13. Shi L, Tu N, Patterson PH. Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. Int J Dev Neurosci.2005; doi:10.1016/j.ijdevneu.2004.05.005.

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

14. Patterson HP. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009; doi: 10.1016/j.bbr. 2008.12.016. 15. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol.2014; doi: 10.1038/nrneurol.2014.187. 16. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry. 2014;75:307–15. 17. Ayed A, Embaireeg A, Benawadh A, Al-Fouzan W, Hammoud M, Al-Hathal M, Alzaydai A, et al. Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait. BMC Pregnancy Childbirth. 2020; doi: 10.1186/s12884-020-03461-2. 18. Squire J, Twombly E, Bricker D, Potter L. ASO-3: User's guide. Baltimore: Paul H. Brookes Publishing Co.; 2009. 19. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;doi.org/10.1016/j.ajogmf.2020.100107 20. Maheshwari B, Sharma P, Panwar K, Goswami KG. Evaluation of maternal and fetal outcome in corona positive pregnant women. Int J Reprod Contra Obstet Gynecol. 2020; doi:10.18203/2320-1770.ijrcog20205244. 21. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, Xia S. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9:51-60.

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

22. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet.2020;doi:10.1016/S0140-6736(20)30360-3. 23. Smith V, Seo D, Warty R, Payne O, Salih M, Chin KL, et al. Maternal and neonatal outcomes associated with COVID-19 infection: A systematic review. PLoS One. 2021; doi.org/10.1371/journal.pone.0234187. 24. Cordeiro CN, Tsimis M, Burd I. Infections and brain development. Obstetrical & gynecological survey. 2015; doi: 10.1097/OGX.000000000000236. 25. Curcio AM, Shekhawat P, Reynolds AS, Thakur KT. Neurologic infections during pregnancy. In Handbook of Clinical Neurology. Elsevier; 2020. p. 79-104. 26. Hassan N, Muzamil M, Banday D. COVID-19 infection during pregnancy - maternal and perinatal outcomes: a tertiary care center study. Int J Reprod Contracept Obstet Gynecol. 2020; doi:org/10.18203/2320-1770.ijrcog20203853. 27. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020; doi: 10.1542/peds.2020-0702. 28. Lu X, Zhang L, Du H. SARS-CoV-2 infection in children. N Engl J Med.2020; doi: 10.1056/NEJMc2005073. 29. ShekerdemianLS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr.2020; doi:10.1001/jamapediatrics.2020.1948.

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

30. Alzamora MC, Paredes T, Caceres D, Webb C, Valdez LM, La Rosa M. Severe COVID-19 during Pregnancy and Possible Vertical Transmission. Am J Perinatol. 2020; doi:10.1055/s-0040-1710050. 31. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet.2020;doi:10.1016/S0140-6736(20)30360-3. 32. Peng Z, Wang J, Mo Y, Duan W, Xiang G, Yi M, et al. Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report. J Infect Public Health. 2020; doi: 10.1016/j.jiph.2020.04.004. 33. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/ (2019). 34. Faure-Bardon V, Magny JF, Parodi M, Couderc S, Garcia P, Maillotte AM, et al. Sequelae of congenital cytomegalovirus following maternal primary infections are limited to those acquired in the first trimester of pregnancy. Clin Infect Dis. 2019; doi: 10.1093/cid/ciy1128. 35. Adams Waldorf KM, McAdams RM. Influence of infection during pregnancy on fetal development. Reproduction. 2013; doi: 10.1530/REP-13-0232. 36. Halai UM, Nielsen-Saines K, Moreira ML, Sequeira PC, Pereira Junior JS, Zin AA, et al. Maternal Zika virus disease severity, virus load, prior dengue antibodies, and their relationship to birth outcomes. Clin Infect Dis. 2017; doi: 10.1093/cid/cix472.

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

37. Dodd KC, Michael BD, Ziso B, Williams B, Borrow R, Krishnan A.Herpes simplex virus encephalitis in pregnancy-a case report and review of reported patients in the literature. BMC Res Notes 2015; doi:10.1186/s13104-015-1071-6. 38. Huddy CLJ, A Johnson A, Hope PL. Educational and behavioral problems in babies of 32–35 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001; doi: 10.1136/fn.85.1.F23. 39. Ellman LM, Yolken RH, Buka SL, Torrey EF, Cannon TD. Cognitive functioning prior to the onset of psychosis: the role of fetal exposure to serologically determined influenza infection. Biol Psychiatry. 2009;doi: 10.1016/j.biopsych.2008.12.015. 40. Parboosing R, Bao Y, Shen L, Schaefer CA, Brown AS. Gestational influenza and bipolar disorder in adult offspring. JAMA Psychiatry.2013; doi: 10.1001/jamapsychiatry.2013.896. 41. Salemi JL, Whiteman VE, August EM, Chandler K, Mbah AK, Salihu HM. Maternal hepatitis B and hepatitis C infection and neonatal neurological outcomes. J Viral Hepat. 2014; doi: 10.1111/jvh.12250. 42. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–40. 43. Rudolph MD, Graham AM, Feczko E, Miranda-Dominguez O, Rasmussen JM, Nardos R, et al. Maternal IL-6 during pregnancy can be estimated from newborn brain connectivity and predicts future working memory in offspring. Nat Neurosci. 2018;doi: 10.1038/s41593-018-0128-y.

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

44. Mao L, Jin H, Wang M, Hu Y, Chen S, Quanwei He O, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; doi:10.1001/jamaneurol.2020.1127. 45. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM, et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res. 2010; doi:10.1016/j.schres. 2010.05.014. 46. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al. The fetal inflammatory response syndrome. Clin Obstet Gynecol. 2007; doi: 10.1097/GRF.0b013e31811ebef6. 47. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun. 2001; 15:411–420. 48. Wong YP, Tan GC, Wong KK, Swaminathan A, Cheah FC. Gardnerella vaginalis in perinatology: An overview of the clinicopathological correlation. Malays J Pathol.2018;doi: org/10.3389/fped.2020.593802. 49. Seethy AA, Singh S, Mukherjee I, Pethusamy K, Purkayastha K, Sharma JB, et al. Potential SARS-CoV-2 interactions with proteins involved in trophoblast functions—An in-silico study. Placenta. 2021; doi: 10.1016/j.placenta.2020.10.027. 50. Wang Y, Chen L, Wu T, Shi H, Qin Li, Jiang H, et al. Impact of Covid-19 in pregnancy on mother's psychological status and infant's neurobehavioral development: a longitudinal cohort study in China. BMC Medicine.2020; doi: https://doi.org/10.1186/s12916-020-01825-1.

Table 1: Maternal and neonatal demographic and clinical characteristics

Variable	All (N= 298)				
Maternal characteristics, N (%) or median (IQR)					
Age (years)		31 (27-35)			
Parity		3 (2-4)			
Gestational diabetes		51 (17.1%)			
Pregnancy-induced hypertension		26 (8.7%)			
	Maternal na	tionality			
Kuwaiti	112 (37.6%)	Non-Kuwai	ti	186 (62.4%)	
	Maternal educa	tional level			
Educated	297 (99%)	Non-educate	ed	3 (1%)	
Elementary school	8 (2.7%)	Middle scho	ool	49 (16.4%)	
High school	38 (12.7%)	Diploma ho	lder	47 (15.8%)	
Bachelor	147 (49.3%)	Master and	PhD	6 (2%)	
	Paternal educa	tional level			
Educated	297 (99.3%)	Non-educate	ed	2 (0.7%)	
Elementary school	6 (2%)	Middle scho	ool	41 (13.8%)	
High school	66 (22.2%)	Diploma ho	lder	57 (19.2%)	
Bachelor	119 (40.1%)	Master and PhD		6 (2%)	
Gestational age at SARS-CoV-2 infection					
<i>I<sup>st</sup> Trimester</i> 5 (1.7%)	2 <sup>nd</sup> Trimester	20 (6.7%)	3 <sup>rd</sup> Trimester	273 (91.6%)	
(< 13 weeks)	(13-26 weeks)		(> 26 weeks)		
Maternal fever		123 (42%)			
Asymptomatic		103 (39.5%)	)		

Severe maternal COVID-19	12 (6.9%)
Maternal ECMO	3 (1%)
Maternal total duration of symptoms, days	5.5 (3-10)

# Neonatal characteristics, N (%), median (IQR)

Mode of delivery					
Vaginal birth	170 (57%)	Cesarean se	ection	128 (43%)	
Multiple gestation		13 (6%)			
Gestational age, weeks		38 (37-39)			
Birth weight, grams		3005 (2660	-3440)		
Male	167 (56%)	Female		131 (44%)	
Ne	eonatal ICU adn	nission (N=70	6)		
Prematurity	55 (18.4%)	Neonatal		6 (2%)	
		hyperbilirubinemia			
Transient tachypnea of newborn	6 (2%)	Congenital heart disease		2 (0.7%)	
Hypoxic-ischemic	3 (1%)	Myelomeningocele		1 (0.3%)	
encephalopathy					
Aqueduct stenosis	1 (0.3%)	Epidermolysis bullosa		1 (0.3%)	
Early-onset Klebsiella sepsis	1 (0.3%)				
SARS-CoV-2 infection PCR		2 (0.7%)			
Type of feeding in the first 6 months of age					
<b>Bottle</b> 50 (50.7%)	Breastfeeding	75	Mixed	71 (24%)	
feeding	(breast milk)	(25.3%)	feeding		
(formula)					

Further hospitalization in the first 8-10 months 28 (9.6%) of life *Values are expressed as numbers (N) and percentages or medians and interquartile ranges* (IQRs). Severe COVID-19: Defined as clinical signs of pneumonia plus SpO<sub>2</sub> less than 90% in room air or admission to an intensive care unit (ICU) for respiratory support (i.e., high-flow nasal cannula, noninvasive mechanical ventilation, and intubation). ECMO: extracorporeal membrane oxygenation. 

	Variable	Developmental	No delay	P value
		delays	N= 268	
		N= 30		
Age, years		33 (30-37)	31 (27-35)	0.089
Parity		2 (2-4)	3 (2-4)	0.373
Gestational diabe	etes	4 (13.3%)	47 (17.5%)	0.562
Pregnancy-induce	ed hypertension	4 (13.3%)	22 (8.2%)	0.346
Maternal	Kuwaiti	9 (30%)	103 (38.4%)	0.366
nationality	Non-Kuwaiti	21 (70%)	165 (61.6%)	
Educational	Diploma and above	20 (66.7%)	180 (67.2%)	0.956
level				
Gestational age	1 <sup>st</sup> trimester	4 (13.3%)	1 (0.4%)	< 0.001
at SARS-CoV-2	2 <sup>nd</sup> trimester	6 (20%)	14 (5.2%)	*
infection	3 <sup>rd</sup> trimester	20 (66.7%)	253 (94.4%)	
Maternal fever		10 (35.7%)	113 (42.8%)	0.47
Asymptomatic		11 (37.9%)	92 (39.7%)	0.858
Severe maternal COVID-19		1 (6.7%)	11 (6.9%)	0.966
Maternal ECMO		0	3 (1.1%)	0.879
Maternal total du	ration of symptoms	5 (3-10)	7 (3-10)	0.651
Mode of	Vaginal birth	14 (46.7%)	156 (58.2%)	0.226
delivery	Cesarean section	16 (53.3%)	112 (41.8%)	
Multiple gestation	n	0	13 (6.4%)	0.312

Gestational age,	weeks, median (IQR)	38 (37-39)	38 (37-39)	0.922
Gestational age	28-30 <sup>+6</sup> weeks	3 (10%)	2 (0.8%)	0.002*
	31-34 <sup>+6</sup> weeks	1 (3.3%)	8 (3%)	
	35-36 <sup>+6</sup> weeks	2 (6.7%)	39 (14.5%)	
	>37 weeks	24 (80%)	219 (81.7%)	
Birth weight, gra	ams	2950 (2400-3400)	3030 (2680-	0.355
			3440)	
Male		13 (43.3%)	154 (57.5%)	0.139
SARS-CoV-2 in:	fection PCR	0	2 (0.7%)	0.363
Neonatal	Prematurity	6 (20%)	49 (18.3%)	0.818
diagnosis	Neonatal hyperbilirubinemia	1 (3.3%)	5 (1.9%)	
	Transient tachypnoea of the	2 (6.6%)	4 (1.5%)	
	newborn			
	Hypoxic-ischemic	1 (3.3%)	1 (0.4%)	
	encephalopathy			
	Congenital heart disease	0	1 (0.4%)	
	Myelomeningocele	0	1 (0.4%)	
	Aqueduct stenosis	0	1 (0.4%)	
	Early-onset <i>Klebsiella</i> sepsis	0	1 (0.4%)	
	Epidermolysis bullosa	0	1 (0.4%)	
Type of feeding	Bottle feeding (formula)	13 (43.3%)	137 (51.5%)	0.690
in the first 6	Breastfeeding (breast milk)	9 (30%)	66 (24.8%)	
months of age	Mixed feeding	8 (26.7%)	63 (23.7%)	

Further hospitalization in the 1<sup>st</sup> 8-10 months of 2 (6.7%) 26 (9.9%) 0.57 life Values are expressed as number (N) and percentage or median and interquartile range (IQR)Severe COVID-19: Defined as clinical signs of pneumonia plus SpO<sub>2</sub> less than 90% in room air or admission to intensive care unit (ICU) for respiratory support (i.e., high-flow nasal cannula, noninvasive mechanical ventilation, and intubation). ECMO: extracorporeal membrane oxygenation. **Table 3:** Multiple regression analysis of the association of demographic and clinical characteristics with developmental delays (ASQ-3 score less than 2 standard deviations below the population mean)


586

587

588

Variable		Adjusted odds	95% CI	P value
		ratio		
Trimester at	3 <sup>rd</sup>	Reference		
SARS-CoV-2	$2^{\text{nd}}$	8.1	2.4-27.7	0.001*
infection	1 <sup>st</sup>	8.2	1.1-55.9	0.039*
Maternal age		1.04	0.96-1.1	0.305
Gestational age at	28-30 <sup>+6</sup> weeks	7.7	0.69-85.8	0.090
birth	31-34 <sup>+6</sup>	1.2	0.13-10.7	0.870
	35-36 <sup>+6</sup>	0.5	0.10-2.3	0.371
	>37	Reference		
Maternal education	Maternal education (diploma and		0.59-5.4	0.300
above)				
Father education (	diploma and	0.5	0.2-1.3	0.172
above)				
Male		1.6	0.68-3.5	0.297
Type of feeding	Mixed feeding	Reference		
in the first 6	Bottle feeding	1.3	0.46-3.4	0.652
months	(formula)			
	Breastfeeding	0.5	0.14-1.6	0.239
	(breast milk)			

Values are expressed as adjusted odds ratios and 95% confidence intervals (95% CIs).



# **Figure Legends:**

Figure 1: Flowchart of the study recruitment and follow-up. ASQ-3: Ages and Stages Questionnaire, 3rd edition 




Figure 2: Developmental outcome using the Ages and Stages Questionnaire, 3rd edition, at 10-12 months of age

A bar graph presenting the total score and subscale scores of ASQ-3 domains.

A score with a standard deviation (SD)  $\leq 2$  below the population mean implies developmental delays, and a score with an SD >2 above the population mean is considered no delay.